Study of Repeated Administration of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic Clinical Trial

— IP-006  

Official title:

An Open-label Study of the Safety and Tolerability of Repeated Administration of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03427151
• Other study ID #: IPP-201101/006
• Status: Completed
• Phase: Phase 3
• Start date: February 27, 2018
• Est. completion date: February 5, 2019

Study information

• Verified date: April 2019
• Source: ImmuPharma
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

this study extension objective is to evaluate the safety and tolerability of a 200-mcg dose every 4 weeks for 24 weeks of IPP-201101 in patients with active systemic lupus erythematosus (SLE) who had participated in the main study IP-005.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 62
• Est. completion date: February 5, 2019
• Est. primary completion date: February 5, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient had participated previously to study IP-005

• Written informed consent is obtained.

• Female and males receiving IPP-201101 and their female partners must use a highly effective contraceptive during treatment and for 30 days after discontinuation of study drug treatment.

• Women must be surgically sterile, 2 years postmenopausal, or, if of childbearing potential, use a highly effective method of contraception, Men and their partner must have highly effective accepted method of contraception. Single barrier/Double barrier and spermicides are not acceptable methods of contraception. Highly effective methods of contraception include, true abstinence, intrauterine device (IUD), or hormonal contraception associated with inhibition of ovulation (oral, transdermal, implanted, and injected), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion, vasectomised partner. True abstinence is defined when this is in line with the preferred and usual lifestyle of the subject." [Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods), declaration of abstinence for the duration of a trial, and withdrawal are not acceptable methods of contraception]

• If the patient is using oral corticosteroids, the weekly cumulative dose must not exceed 80 mg of prednisone equivalent; the weekly dose must be stable over the 4 weeks preceding the 1st dose of study drug.

• If the patient is using antimalarials, methotrexate, leflunomide, mycophenolate mofetil (MMF), or azathioprine, the start date must be at least 3 months prior to the 1st dose of study drug, and the daily dose must be stable over the 4 weeks preceding the 1st dose of study drug.

• If the patient is not currently using corticosteroids, antimalarials, methotrexate, MMF, or azathioprine, the last dose (in case of previous use) must be at least 4 weeks prior to the 1st dose of study drug. For leflunomide, the stop date must be at least 8 weeks before the 1st dose of study drug unless an adequate cholestryamine washout has been performed. If cholestyramine washout is performed, the last use of leflunomide must be at least 4 weeks before the 1st dose of study drug.

• The patient must be willing and able to comply with study restrictions, to remain at the study center for the required duration during each study visit, and to return to the study center for the final assessment as specified in this protocol.

Criteria for Exclusion: Patients are excluded from participating in this study if 1 or more of the following criteria are met:

• The patient has been treated with intramuscular or intravenous (iv) pulse steroids (ie, 250 to 1000 mg iv total daily dose of methylprednisolone) within 4 weeks of the 1st dose of study drug. The use of intra-articular steroids may be allowed after consultation with the medical expert.

• The patient has received tacrolimus, cyclosporin A, or iv immunoglobulins (IVIG) within 3 months of the 1st dose of study drug.

• The patient has received cyclophosphamide within 6 months prior to the 1st dose of study drug.

• The patient has been treated for SLE with agents such as fusion proteins, therapeutic proteins, or monoclonal antibodies or antibody fragments, within 6 months of the 1st dose of study drug.

• The patient has received B-cell depleting agents such as rituximab or belimumab or epratuzumab within one year of the 1st dose and has not yet normalized the B-cell count (ie, CD20+ B-cell count is less than normal range and the absolute lymphocyte count [ALC] is less than normal range).

• The patient has New York Heart Association (NYHA) Class III or IV congestive heart failure.

• The patient has an estimated glomerular filtration rate (eGFR) of less than 30 mL/min/1.73 m2 (via Modification of Diet in Renal Disease [MDRD] equation).

• The patient has an aspartate aminotransferase (AST) or alanine aminotransferase (ALT) value greater than 2 times the upper limit of the normal range (ULN) or a total bilirubin level greater than 1.5 times ULN.

• The patient has a planned immunization with a live or live attenuated vaccine within 3 months prior to administration of the 1st dose of study drug and for 3 months after administration of the last dose of study drug.

• The patient has any clinically significant abnormalities on ECG that are not related to SLE, as determined by the investigator. Patients with stable ECG changes without evidence of active cardiovascular disease may participate at the discretion of the investigator and medical monitor.

• The patient has an ongoing active systemic infection requiring treatment or a history of severe infection, such as hepatitis or pneumonia, in the 3 months prior to administration of the 1st dose of study drug. Less severe infections in the 3 months prior to administration of the 1st dose of study drug are permitted at the discretion of the investigator and medical monitor.

• The patient has any concomitant medical condition unrelated to SLE that may interfere with his or her safety or with evaluation of the study drug, as determined by the investigator.

• The patient has a history of a medical condition other than SLE that has required treatment with oral corticosteroids in excess of 80 mg of prednisone equivalent/week within 3 months of the 1st dose of study drug.

• The patient has a positive test result for hepatitis B surface antigen (HBsAg) or hepatitis C virus antibody (HCV Ab).

• The patient has a known positive history of antibodies to human immunodeficiency virus (HIV) or HIV disease or other immunosuppressive state (eg, agammaglobulinemia, etc).

• The patient has a history of alcohol or substance dependence or abuse (with the exception of nicotine),according to the Diagnostic and Statistical Manual of Mental Disorders of the American Psychiatric Association, Fourth Edition, Text Revision (DSM-IV-TR), within 3 months of the screening visit or has current substance abuse.

• The patient has a history of severe allergic reactions to or hypersensitivity to any component of the study drug.

• The patient has undergone or is undergoing treatment with another investigational drug for the treatment of lupus within 6 months prior to the 1st dose of study drug or has received any other investigational drug for any other condition within 4 weeks prior to the 1st dose of study drug except for IPP-201101

• The patient is a pregnant or lactating woman. (Any women becoming pregnant during the study will be withdrawn from the study.)

• The patient is unlikely to comply with the study protocol or is unsuitable for any other reason, as judged by the investigator or medical monitor.

Related Conditions & MeSH terms

• Lupus Erythematosus, Systemic

Intervention

Drug:
• IPP-201101
200 mcg of IPP-201101 will be administered subcutaneously every 4 weeks for 24 weeks.

Locations

Country	Name	City	State
Czechia	Revmatologie s.r.o.	Brno
Czechia	Revmatologický ústav v Praze	Praha
France	GHR Mulhouse Sud-Alsace	Mulhouse
France	CHU de la Réunion	Saint-Denis
Germany	Schlosspark-Klinik Berlin	Berlin
Germany	Clinic for Rheumatology and Internal Medicine	Freiburg
Hungary	University of Debrecen Medical Center Department of Clinical Immunology	Debrecen
Hungary	Mentaház Magánorvosi Központ Kft.	Székesfehérvár
Mauritius	CAP Research	Phoenix
Puerto Rico	Latin Clinical Trial Center	San Juan
United States	Arthritis and Rheumatic Disease Specialties	Aventura	Florida
United States	Innovative Health Research	Las Vegas	Nevada
United States	WALLACE	Los Angeles	California
United States	East Bay Rheumatology Medical	San Leandro	California

Sponsors (1)

Lead Sponsor	Collaborator
ImmuPharma

Countries where clinical trial is conducted

United States,  Czechia,  France,  Germany,  Hungary,  Mauritius,  Puerto Rico, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Occurrence of adverse events throughout the study	all adverse events will be coded using MedDRA and the sverity will be graded according to the modified WHO toxicity Criteria and they will be determined by the Investigator to be treatment related. The incidence of adverse events will be summarized using descriptive statistics by system organ classe and preferred term.	7 months
Primary	Clinical laboratory test results at each visit during the treatment extension period	Summary statistics for laboratory tests will be presented at baseline and at each visit.The severity of select laboratory resuts will be graded accroding the Modified WHO Toxicity Criteria.	7 months
Primary	Body weight measurements at each visit during the treatment period	The incidence of clinically significant abonormal values will be summarized using descriptive statistics.	7 months
Primary	Temperature measurements at each visit during the treatment period	The incidence of clinically significant abonormal values will be summarized using descriptive statistics.	7 months
Primary	Pulse measurements at each visit during the treatment period	The incidence of clinically significant abonormal values will be summarized using descriptive statistics.	7 months
Primary	Systolic and diastolic blood pressures measurements at each visit during the treatment period	The incidence of clinically significant abonormal values will be summarized using descriptive statistics.	7 months
Primary	2-lead electrocardiogram (ECG) findings at week 28 (or final assessment)	Any ECG finding that is judged by the investigator as a clinically significant change (worsening) compared to a baseline value will be considered an adverse event coded using MedDRA	7 months
Primary	Physical examination findings, at specified time points at each visit during the treatment extension period	Body system (General appearance, Skin, HEENT (Head, eyes, ears, nose, throat), Lymph Nodes, Thyroïd, Musculo-skeletal / Extremities, Cardiovascular, Lungs, Abdomen, Neurological) findings that is judged by the investigator as a clinically significant change (worsening) compared to a baseline value will be considered an adverse event coded using MedDRA	7 months
Primary	Concomitant medication usage throughout the study extension	All concomittant medication will be coded using the WHO Drug dictionnary. The incidence of concomittant medications will be sumamrized using descriptive statistics by therapeutic class and preferred terms category.	7 months
Secondary	the effect in the Clinical SLEDAI-2K total score by at final visit compared to initial visit	The SLEDAI 2K is a validated objective measure that assesses disease activity within the last 28 days before completion of the index. It is a global index and includes 24 weighted clinical and laboratory variables. The SLEDAI-2K clinical score is the calculated score without inclusion of the points that may be contributed by having a psoitive titer fr anti-dsdna Ab or decreased serum complement level. The SLEDAI-2K clinical score (sum of 22 scores) ranges from 0 to 101.	at week 28
Secondary	remission of the disease (i.e reduction of clinical SLEDAI-2K score to 0)		at week 28